Oncotarget

Research Papers:

The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes

Francesca Coperchini, Laura Croce, Marco Denegri, Oriana Awwad, Samuel Tata Ngnitejeu, Flavia Magri, Luca Chiovato and Mario Rotondi

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2019; 10:6432-6443. https://doi.org/10.18632/oncotarget.27266

Metrics: PDF 25 views  |   HTML 28 views  |   ?  


Abstract

Francesca Coperchini1, Laura Croce1,2, Marco Denegri3, Oriana Awwad4, Samuel Tata Ngnitejeu5, Flavia Magri1,6, Luca Chiovato1,6 and Mario Rotondi1,6

1 Istituti Clinici Scientifici Maugeri IRCCS, Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Pavia, Italy

2 PHD course in Experimental Medicine, University of Pavia, Pavia, Italy

3 Molecular Cardiology, ICS-Maugeri, Pavia, Italy

4 Department of Biopharmaceutics and Clinical Pharmacy, The University of Jordan, Amman, Jordan

5 Department of General and Minimally Invasive Surgery, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy

6 Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

Correspondence to:

Luca Chiovato,email: luca.chiovato@icsmaugeri.it

Keywords: phenformin; tumor-microenvironment; thyroid cancer; CXCL8

Received: August 12, 2019     Accepted: September 24, 2019     Published: PUBLISHED_DATE

ABSTRACT

Phenformin is a biguanide drug which, besides the original anti-diabetic effect, also exerts anti-cancer effects. The aim of this study was to further characterize these latter in terms of both cell-viability and modulation of the secretion of the pro-tumorigenic chemokine CXCL8. Normal human thyrocytes in primary cultures (NHT) and thyroid cancer cell lines, TPC-1 and 8505C (RET/PTC and BRAFV600E mutated, respectively) were treated with increasing concentrations of phenformin at different times. Cell-viability was assessed by WST-1 and further characterized by AnnexinV/PI staining and cell proliferation colony-assay. CXCL8 levels were measured in cell supernatants. Phenformin reduced cell-viability in TPC-1 and 8505C and their ability to form colonies. In NHT cells, phenformin affected cell-viability only at the maximal dose but interestingly it inhibited CXCL8 secretion at all the concentrations not affecting cell-viability. Phenformin had no effect on CXCL8 secretion in thyroid cancer cell lines. Thus, phenformin exerts anti-cancer effects on both cancer cells (cell death induction) and surrounding normal cells (inhibition of CXCL8 secretion). These results highlight that the anti-cancer effects of phenformin are multifaceted and effective on both solid and soluble components of the tumor-microenvironment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27266